AstraZeneca announced it has commenced Ph III trials of AZD1222. Up to 30,000 adults in the US will be recruited, with testing sites also in Peru, Chile, UK, Brazil and South Africa. The results of the trial are anticipated later this year.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Aug 31, 2020
AstraZeneca announced it has commenced Ph III trials of AZD1222. Up to 30,000 adults in the US will be recruited, with testing sites also in Peru, Chile, UK, Brazil and South Africa. The results of the trial are anticipated later this year.
By Bioblast Editor | Aug 28, 2020
Healio reports the results of the UK Kings College/NHS Trust MERLOT trial demonstrated there was no benefit to epimacular brachytherapy as an adjunct to anti-VEGF injections, the results of which were worse than ranibizumab monotherapy, for the treatment of neovascular age-...
By Bioblast Editor | Aug 28, 2020
Cadila Pharmaceuticals launches Cadalimab® (biosimilar adalimumab) in India. Cadalimab® is available in 40mg/0.8mL injection and is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. This is the four...
By Pearce IP | Aug 27, 2020
First published in Australian Intellectual Property Law update Vol. 33, No. 2, Jun 2020: 35-38
The COVID-19 pandemic and the urgent global need for effective treatments and/or...
By Bioblast Editor | Aug 27, 2020
Rheumatology Advisor reports a study sponsored by China’s National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation demonstrates that delayed administration of subsequent denosumab doses by greater than 16 weeks is associated with increas...
By Bioblast Editor | Aug 26, 2020
Multiple Sclerosis News Today reports a new real-life study demonstrates that Ocrevus® (ocrelizumab) carries a higher risk of infections but carries a lower risk of cancer and immune reactions than rituximab in patients with multiple sclerosis.
By Bioblast Editor | Aug 26, 2020
The Midwest Business Group on Health (MBGH) issued a call to action on biosimilars. In this call to action, the MBGH highlighted the missed opportunities for cost savings amid the ever increasing costs for biologic drugs.
By Naomi Pearce | Aug 26, 2020
Significant biosimilar activities this week include
11 Aug 20 | In an online press conference, Samsung Biologics announced it plans for a fourth manufacturing plant within the year. This new US $2 billion plant will have 256KL capacity, with manufacturing activities...
By Naomi Pearce | Aug 26, 2020
On 21 August 2020, PBAC published the results of the July meeting at which PBAC deferred its decision regarding Chiesi’s application to list Epidyolex® (cannabidiol). The PB...
By Bioblast Editor | Aug 26, 2020
Lupin and Mylan launch Nepexto® (biosimilar etanercept) in Germany. Nepexto® is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, severe axial spondyloarthritis and plaque psoriasis.
SUBSCRIBE TO PEARCE IP